GCM
MLAB icon

Geneva Capital Management’s Mesa Laboratories MLAB Stock Holding History

Geneva Capital Management’s Portfolio MLAB Stock Details MLAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-178,713
Closed -$14M – 123
2025
Q4 		$14M Sell
178,713
-12,673
-7% -$964K 0.26% 84
2025
Q3 		$12.8M Sell
191,386
-7,706
-4% -$555K 0.22% 86
2025
Q2 		$18.8M Buy
199,092
+9,780
+5% +$1.07M 0.31% 79
2025
Q1 		$22.5M Buy
189,312
+299
+0.2% +$40.8K 0.42% 70
2024
Q4 		$24.9M Sell
189,013
-2,963
-2% -$364K 0.43% 65
2024
Q3 		$24.9M Buy
191,976
+3,732
+2% +$439K 0.42% 76
2024
Q2 		$16.3M Sell
188,244
-6,086
-3% -$637K 0.3% 84
2024
Q1 		$21.3M Buy
194,330
+4,801
+3% +$484K 0.38% 80
2023
Q4 		$19.9M Sell
189,529
-5,683
-3% -$554K 0.38% 80
2023
Q3 		$20.5M Buy
195,212
+3,542
+2% +$454K 0.43% 76
2023
Q2 		$24.6M Sell
191,670
-3,471
-2% -$529K 0.49% 70
2023
Q1 		$34.1M Buy
195,141
+3,325
+2% +$596K 0.69% 52
2022
Q4 		$31.9M Buy
191,816
+87,031
+83% +$13.6M 0.72% 55
2022
Q3 		$14.8M Buy
+104,785
New +$19.1M 0.34% 90

Other funds holding MLAB

LPP
Long Path Partners Stamford, Connecticut $235M AUM 22.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Diamond Hill Capital Management
Diamond Hill Capital Management Columbus, Ohio $12.5B AUM 7.49% 1-Year Est. Return

Geneva Capital Management's MLAB Position: Q1 2026 in Review

Geneva Capital Management sold out of Mesa Laboratories (MLAB) in Q1 2026, closing a stake of 178,713 shares — an estimated $14M sold.

Geneva Capital Management first reported a position in MLAB in Q3 2022 and held it in 14 quarters. The position peaked at $34.1M in Q1 2023. 161 funds tracked by Wall St. Rank hold MLAB as of Q1 2026.

  • Geneva Capital Management reported no remaining Mesa Laboratories position as of Q1 2026 after selling out during the quarter.
  • Geneva Capital Management sold 178,713 Mesa Laboratories shares in Q1 2026, an estimated $14M.
  • Geneva Capital Management first reported a position in Mesa Laboratories in Q3 2022 and held it in 14 quarters.
  • Geneva Capital Management's Mesa Laboratories position peaked at $34.1M in Q1 2023.
  • 161 funds tracked by Wall St. Rank held Mesa Laboratories as of Q1 2026.

Based on Geneva Capital Management's 13F filing for Q1 2026, filed 6 May 2026.